In a statement, Neurocrine said it expects to launch the new product within a week. In its third-quarter results call, chief commercial officer Eric Benevich said the drug "has all the ...

This growth was primarily due to high patient demand and improved profit margins. Neurocrine launched a new product, Crenessity, which contributed $2 million in sales, marking its entry into the ...

Neurocrine Biosciences announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, though the ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

Yet that was the dynamic with Neurocrine, with prognosticators at H.C. Wainwright, Guggenheim, and UBS (NYSE: UBS) all getting simultaneously less bullish on the company's future. Where to invest ...

RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...

Neurocrine Biosciences announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, though the company ...